NICE (UK) positive for Retevmo (selpercatinib) for previously treated RET fusion-positive advanced non-small-cell lung cancer – Eli Lilly
NICE (UK): Selpercatinib is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults,… read more.
